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Abstract: The metabolism of vandetanib, a tyrosine kinase inhibitor used for treatment of symptomatic/
progressive medullary thyroid cancer, was studied using human hepatic microsomes, recombinant
cytochromes P450 (CYPs) and flavin-containing monooxygenases (FMOs). The role of CYPs and FMOs
in the microsomal metabolism of vandetanib to N-desmethylvandetanib and vandetanib-N-oxide was
investigated by examining the effects of CYP/FMO inhibitors and by correlating CYP-/FMO-catalytic
activities in each microsomal sample with the amounts of N-desmethylvandetanib/vandetanib-N-oxide
formed by these samples. CYP3A4/FMO-activities significantly correlated with the formation of
N-desmethylvandetanib/vandetanib- N-oxide. Based on these studies, most of the vandetanib metabolism
was attributed to N-desmethylvandetanib/vandetanib-N-oxide to CYP3A4/FMO3. Recombinant CYP3A4
was most efficient to form N-desmethylvandetanib, while FMO1/FMO3 generated N-oxide. Cytochrome
b5 stimulated the CYP3A4-catalyzed formation of N-desmethylvandetanib, which is of great importance
because CYP3A4 is not only most efficient in generating N-desmethylvandetanib, but also most significant
due to its high expression in human liver. Molecular modeling indicated that binding of more than
one molecule of vandetanib into the CYP3A4-active center can be responsible for the high efficiency
of CYP3A4 N-demethylating vandetanib. Indeed, the CYP3A4-mediated reaction exhibits kinetics of
positive cooperativity and this corresponded to the in silico model, where two vandetanib molecules
were found in CYP3A4-active center.
Keywords: vandetanib; tyrosine kinase inhibitor; metabolism; cytochromes P450; flavin-containing
monoxygenases
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1. Introduction
Studies carried out over the last decades demonstrate that drugs used for cancer chemotherapy
have a narrow therapeutic index, and often the produced responses are only palliative and unpredictable.
Although such approaches are directed towards certain biomacromolecules, they often do not
discriminate between rapidly dividing tumor vs non-malignant cells [1,2]. In contrast, targeted
therapy has been introduced in recent years, which is directed against cancer-specific targets and
signaling pathways thus providing more limited nonspecific mechanisms [3]. The most promising
targets include receptor tyrosine kinases (TKs), enzymes that selectively phosphorylate hydroxyl
moieties of tyrosine residues on signal transduction molecules with a phosphate moiety from adenosine
triphosphate [4,5]. Therefore, inhibitors of these enzymes, tyrosine kinase inhibitors (TKIs), are now
considered as promising small molecules for the treatment of several types of cancer including the
thyroid carcinomas [5].
Vandetanib (Caprelsa, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)-methoxy]-
quinazolin-4-amine; Figure 1) is a TKI—it inhibits vascular endothelial growth factor receptor 2 (VEGFR-2),
epidermalgrowthfactorreceptor(EGFR)andrearrangedduringtransfection(RET)tyrosinekinaseactivity[6–10].
It has also activity against protein tyrosine kinase 6 (BRK), tyrosine kinase with immunoglobulin and epidermal
growth factor (EGF) domains-2 (TIE2), members of the ephrin receptor kinase family, and members of the
SRC family of tyrosine kinases [11]. Therefore, vandetanib is considered a multiple TKI. Its administration
reduces tumor cell-induced angiogenesis, tumor vessel permeability, and inhibits tumor growth and metastasis
in mouse models of cancer [11]. These activities result from their major targets; VEGFR-2, EGFR and RET,
because they are all involved in signaling pathways promoting angiogenesis and tumor growth [10,12–14].
Vandetanib is used for the treatment of symptomatic or progressive medullary thyroid cancer, probably because
the RET tyrosine kinase mutation occurs in this type of thyroid cancer [11,15–18]. Treatment with vandetanib
is usually well-tolerated by patients but is contraindicated in people with congenital long QT syndrome.
In addition, various side effects such as diarrhea, rash and/or nausea can occur [19,20].
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Figure 1. Vandetanib oxidation by CYP and FMO enzymes. Cytochrome b5 (cyt b5).
In cancer chemotherapy, serious clinical consequences may occur from small alterations in drug
metabolism affecting drug pharmacokinetics [21]. Although in general there is only little known about
the metabolism of TKIs, the metabolism of vandetanib has been investigated, mainly in studies carried
out by AstraZeneca [10,11,20,22,23] but also others [24]. The metabolism of vandetanib in human was
shown to be the same as that observed in experimental animal models such as rat, mouse and dog.
N-desmethylvandetanib and vandetanib-N-oxide (Figure 1) were found as major metabolites in excreta
of humans and experimental animals [10,20]. In mice and rats, O-desmethylvandetanib glucuronide
Int. J. Mol. Sci. 2019, 20, 3392 3 of 22
was found as minor metabolite [10,20,24]. This glucuronide conjugate was also detected in human
urine. In healthy male subject’s administration of radiolabeled vandetanib confirmed the presence of
N-desmethylvandetanib and vandetanib-N-oxide in plasma, urine and feces [10]. Both metabolites
have shown in vitro pharmacologic activity in cellular assays for VEGFR and EGFR [10].
Studies carried out by AstraZeneca have indicated that cytochrome P450 (CYP) and flavin-
containing monooxygenase (FMO) enzymes are involved in the metabolism of vandetanib [10,23].
While CYP3A4 was considered as the major enzyme oxidizing vandetanib to N-desmethylvandetanib,
FMOs expressed in the kidney (FMO1) and liver (FMO3) (Figure 1) were suggested to be responsible
for the formation of vandetanib-N-oxide [10,23]. However, some other studies did not fully confirm
these results, showing contrasting results. For example, itraconazol, a strong inhibitor of CYP3A4 was
almost ineffective in inhibiting the formation of N-desmethylvandetanib after vandetanib treatment,
which would indicate a relative low potency of this enzyme to catalyze this oxidation reaction [10].
Because information on the oxidation of vandetanib by other biotransformation enzymes is absent in the
current literature, metabolic studies are needed to further characterize enzymes capable of oxidizing
vandetanib. Firstly, these studies are important because vandetanib metabolites exhibit rather different
pharmacological efficiencies compared to the parent drug. While N-desmethylvandetanib possesses
similar potency as vandetanib, vandetanib-N-oxide is more than 50-fold less active than the parent
drug [10]. Hence, the metabolism of vandetanib might determine its pharmacological (anticancer)
efficiency. Secondly, confirming results demonstrating that vandetanib is oxidized by CYP3A4 or
identifying additional CYPs (or other biotransformation enzymes) capable of metabolizing vandetanib
is important to evaluate whether a patient’s response to vandetanib is influenced by other host factors
(e.g., genetic polymorphisms). Inhibition or induction of these biotransformation enzymes by various
agents would influence the efficacy of vandetanib during treatment. This is a reasonable scenario
because oncology patients frequently take a wide range of other drugs in addition to their therapy for
cancer, possibly including compounds that can induce or inhibit enzymes metabolizing anticancer drugs.
Significant pharmacokinetic drug–drug interactions can lead to alterations in plasma concentrations of
vandetanib, potentially resulting in a reduction in efficacy or an increase in drug-related toxicity.
In the present study we investigated the in vitro metabolism of vandetanib in cell-free systems.
We used hepatic subcellular systems (microsomes) isolated from the human livers which are rich
in enzymes metabolizing a variety of different drugs and other xenobiotics. In addition, individual
recombinant human CYP and FMO enzymes were employed to identify enzymes capable of oxidizing
this drug. Because CYP3A4 was identified as the major enzyme metabolizing vandetanib in human liver,
the mechanism of the CYP3A4-catalyzed oxidation of vandetanib which determines its pharmacological
efficiencies, was characterized in detail. Further, since the heme protein cytochrome b5 plays
an important role in CYP3A4-mediated microsomal oxidative reactions, for example testosterone
6β-hydroxylation, ellipticine oxidation and nifedipine oxidation [25–29], its effects on vandetanib
oxidation by CYP enzymes were also investigated.
2. Results
2.1. Oxidation of Vandetanib by Human, Rat, Mouse and Rabbit Hepatic Microsomes
First, we investigated the function of human hepatic microsomal subcellular systems containing
biotransformation enzymes to catalyze the oxidation of vandetanib and compared it with the efficiency
of enzymes present in hepatic microsomes isolated from experimental animals, which were considered
as models to mimic the fate of vandetanib in humans [10]. For this comparison human, rat, rabbit and
mouse hepatic microsomes were utilized in the present study. All liver microsomes oxidized vandetanib
to two metabolites that were separated by HPLC (Figure 2) and identified by mass spectrometry as
N-desmethylvandetanib and vandetanib-N-oxide (Figure 3). The formation of vandetanib metabolites
was dependent on nicotinamide adenine dinucleotide phosphate reduced (NADPH) which serves
as cofactor for both POR-mediated CYP catalysis and FMO-mediated oxidative reactions in human,
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rat, rabbit and mouse liver microsomes (Figure 2). Without NADPH no oxidation of vandetanib was
detected (Figure 2).
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Figure 4. Oxidation of vandetanib by human, rat, rabbit and mouse hepatic microsomes. Values 
represent mean ± SD of three independent in vitro incubations (n = 3). F, fold difference between 
formation of N-desmethylvandetanib and vandetanib-N-oxide. *** p < 0.001 significant differences 
between formation of N-desmethylvandetanib and vandetanib-N-oxide (ANOVA with post-hoc 
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Figure 3. MS spectrum of vandetanib products measured by 12T electrospray ionization coupled
with Fourier-transform ion cyclotron resonance (ESI-FTICR). Vandetanib was observed as singly and
doubly charged ion at m/z 475.1144 (1+) and m/z 238.0607 (2+) (∆ppm 1.0). Insert A represents the
detail mass spectrometry (MS) spectrum of the vandetanib metabolite N-desmethylvandetanib at m/z
461.0990 (∆ppm 1.5). Insert B represents the detail MS spectrum of the vandetanib metabolite N-oxide
of vandetanib at m/z 491.1098 (∆ppm 1.8).
These results demonstrated that the oxidation of vandetanib in hepatic microsomes is mediated
by CYPs and/or FMOs. Human hepatic microsomes produced mainly N-desmethylvandetanib,
while vandetanib-N-oxide was formed at ~4-fold lower amounts (p < 0.001). In contrast, rat, rabbit and
mouse hepatic microsomes oxidized vandetanib to vandetanib-N-oxide at 4- to 8-fold higher amounts
than N-desmethylvandetanib (p < 0.001) (Figure 4).
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In order to identify individual human CYPs and/or FMOs oxidizing vandetanib and estimate
their contribution to the oxidation process, three approaches were utilized: (i) use selective CYP and
FMO inhibitors in human hepatic microsomes; (ii) correlation of CYP- and FMO-linked activities
in human hepatic microsomes with the amounts of vandetanib metabolites generated by the same
microsomes; and (iii) use recombinant human CYPs and FMOs. In addition, analysis of the data on
the CYP-mediated formation of N-desmethylvandetanib by individual human recombinant CYPs
in combination with the CYP enzyme expression levels in human livers was employed to evaluate
CYP contributions to this reaction in human livers.
2.2. The Effects of CYP and FMO Enzyme Inhibitors on Vandetanib Oxidation in Human Liver Microsomes
The role of human hepatic enzymes in vandetanib oxidation was initially investigated by
modulating the enzyme-catalyzed reactions using selective inhibitors of individual CYPs and FMOs
in human hepatic microsomes. Two approaches were utilized in the inhibition studies: (i) evaluation
of the % inhibition at inhibitor concentrations equimolar to that of the substrate (vandetanib);
and (ii) determination of the IC50 values for individual inhibitors. Inhibitors α-naphthoflavone
(α-NF), diamantane, sulfaphenazole, quinidine, diethyldithiocarbamate (DDTC) and ketoconazole
evaluated the CYP1A-, 2B-, 2C-, 2D-, 2E1- and 3A-mediated formation of N-desmethylvandetanib,
respectively (Table 1). Ketoconazole was the most efficient in inhibiting the oxidation of vandetanib to
N-desmethylvandetanib, decreasing its formation by 98% at 50 µM. The IC50 for ketoconazole equaled
to 2 µM (Table 1). Under concentrations equimolar to vandetanib, sulfaphenazole and quinidine
inhibited the formation of N-desmethylvandetanib by 38% and 20%, respectively (Table 1). The IC50
values could not be exactly determined, since even at concentrations of 500 µM, the inhibition was less
than 50%. Inhibitors of other CYPs (α-NF, diamantane and DDTC) showed no inhibitory effects on
vandetanib oxidation in human microsomes (Table 1).
Table 1. Effects of CYP and FMO inhibitors on oxidation of vandetanib by human liver microsomes.
Enzymes Inhibitor a
% of Inhibition IC50 (µM)
N-Desmethyvandetanib Formation
CYP
α-Napththoflavone (CYP1A) 0 NA b
Diamantane (CYP2B) 0 NA
Sulfaphenazole (CYP2C) 38 ± 4 *** NA
Quinidine (CYP2D) 20 ± 4 ** NA
DDTC (CYP2A, CYP2E1) 0 NA
Ketoconazole (CYP3A) 98 ± 3 *** 2 ± 0.2
Vandetanib-N-oxide Formation
FMO Methimazol (FMOs) 79 ± 4 *** 6 ± 0.5
a CYPs for which compounds acts as their specific inhibitors are listed in brackets. Equimolar concentrations
of individual inhibitors and vandetanib (50 µM), 0.1 nmol of microsomal CYP for CYP inhibition and 0.25 mg
of microsomal protein for FMO inhibition were in incubation mixtures. Values represent mean ± SD of three
independent in vitro incubations (n = 3). b NA, not applicable. *** p < 0.001, ** p < 0.01, statistically different from
data of controls, without inhibitors (ANOVA with post-hoc Tukey HSD Test).
None of the tested CYP inhibitors was capable of inhibiting the formation of vandetanib N-oxide.
These results suggest that CYP enzymes do not catalyze the oxidation of vandetanib to its N-oxide and
that CYP3A is most efficient in catalyzing the oxidation of vandetanib to N-desmethylvandetanib.
Methimazole, an inhibitor of FMO [30,31], was used to inhibit FMO-catalyzed oxidation of vandetanib.
Formation of vandetanib-N-oxide in human liver microsomes was inhibited by 79% at equimolar
concentrations to vandetanib, having an IC50 value of 6 µM (Table 1). Therefore, FMO can be responsible
for oxidation of vandetanib to vandetanib-N-oxide in human hepatic microsomes. In this context,
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it is noteworthy that methimazole also marginally decreased the formation of N-desmethylvandetanib
in human microsomes (by ~5%), but the observed effect was not statistically significant.
2.3. Correlation of CYP- and FMO-Linked Enzyme Activities in Human Hepatic Microsomes with Vandetanib
Oxidation to N-Desmethylvandetanib and Vandetanib-N-Oxide
To further identify authentic human CYP and FMO enzymes oxidizing vandetanib, hepatic
microsomal samples from livers of 12 different human donors were used in additional experiments.
Whereas all of the human microsomal preparations oxidized vandetanib to N-desmethylvandetanib,
the amounts of vandetanib-N-oxide in several samples were below the limit of detection (Table 2).
Correlations between the CYP/FMO-catalytic activities and the amounts of N-desmethylvandetanib
and vandetanib-N-oxide formed in each microsomal sample (Table 2) were used to examine the role of
specific human CYP and FMO enzymes in their generation. Formation of N-desmethylvandetanib
highly correlated with testosterone-6β-hydroxylation, a marker for CYP3A4 (r = 0.984; p < 0.001, Table 3).
Further, generation of N-desmethylvandetanib also correlated with (S)-mephenytoin-N-demethylase,
a marker for CYP2B6 (r = 0.826; p < 0.001), coumarine-7-hydroxylase, a marker for CYP2A6 (r = 0.778;
p < 0.01), and paclitaxel-6α-hydroxylase, a marker for CYP2C8 (r = 0.747; p <0.01), but not with
the activities of other CYPs and FMO. These findings suggest that CYP3A4, followed by CYP2B6,
2A6 and 2C8 enzymes, could be responsible for the formation of N-desmethylvandetanib in liver
microsomes. However, there is a cross-correlation between testosterone-6β-hydroxylation and
(S)-mephenytoin-N-demethylase activity (r = 0.823; p < 0.001), testosterone-6β-hydroxylation and
coumarine-7-hydroxylase activity (r = 0.786; p < 0.001), and testosterone-6β-hydroxylation and
paclitaxel-6α-hydroxylase activity (r = 0.750; p < 0.01), within these liver samples. To additionally
clarify these correlations, multivariate analysis was used to investigate the dependence of
N-desmethylvandetanib formation on these CYP activities. Activities of CYP2B6, 2A6 and 2C8
in each microsomal sample were combined in pairs with the activities of CYP3A4 to see if any
combination of the activities led to an improvement in the correlation with vandetanib oxidation
to N-desmethylvandetanib, i.e., an increase in the correlation coefficient when compared with the
correlation with the individual activities. However, the inclusion of the CYP2B6 or 2A6 or 2C8 activities
led to no improvement in the correlation coefficient. Therefore, CYP3A4 has the highest impact on the
generation of N-desmethylvandetanib in human hepatic microsomes.
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e (S)-Mephenytoin-N-demethylase—CYP2B6; e Paclitaxel-6α-hydroxylase—CYP2C8; e Diclofenac-4′-hydroxylase—CYP2C9; e (S)-Mephenytoin-4′-hydroxylase—CYP2C19;
e Bufuralol-1′-hydroxylase—CYP2D6; e Chlorzoxazone-6-hydroxylase—CYP2E1; e Testosterone-6β-hydroxylase—CYP3A4-; e Lauric acid-12-hydroxylase—CYP4A11; e Methyl-p-tolyl
sulfide oxidase—FMO; f N-desmethylvandetanib (M1) and vandetanib-N-oxide (M2) in peak area/(mg protein ×min); the detection limit for the formation of metabolite M2 was < 0.002 (in
peak area/(mg protein x min); g Not measured; h ND—not detectable (levels below the limit of detection).
Table 3. Correlation coefficients (r) among CYP- and FMO-linked catalytic activity and amounts of N-demethylvandetanib and vandetanib-N-oxide formed
in microsomes.
Total CYPs POR Cyt b5 CYP1A2 CYP2A6 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP2E1 CYP3A4 CYP4A11 FMO
a M1 0.786 ** 0.700 −0.114 0.018 0.778 ** 0.826 *** 0.747 ** −0.034 −0.168 0.165 0.043 0.984 *** 0.002 0.270
a M2 0.166 0.035 −0.5743 −0.157 −0.339 0.093 0.288 −0.039 0.088 −0.343 0.714 ** −0.200 0.315 0.736 **
*** p < 0.001; ** p < 0.01. a M1—N-desmethylvandetanib; a M2—vandetanib-N-oxide
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The formation of vandetanib-N-oxide was correlated with methyl-p-tolyl sulfide oxidase, a marker
for FMO (r = 0.736; p < 0.01; Table 2), which indicated that vandetanib-N-oxide formation is catalyzed by
FMO within the human hepatic microsomes. However, we also found a correlation between formation
of vandetanib-N-oxide and chlorzoxazone-6-hydroxylase, a marker for CYP2E1 (r = 0.714; p < 0.01)
within these liver samples. Although the cross-correlation between methyl-p-tolyl sulfide oxidase
activity and chlorzoxazone-6-hydroxylase activity (r = 0.552) within these liver samples was weak,
the observed correlation of the FMO activity with the CYP2E1 activity was unexpected. Specifically,
because no inhibition of vandetanib-N-oxide formation was produced by DDTC, an inhibitor of
CYP2E1 (Table 1), and also because human recombinant CYP2E1 did not generate vandetanib-N-oxide
(Figure 5A). Therefore, all these findings strongly suggest that FMO (predominantly FMO3) is the
enzyme responsible for oxidation of vandetanib to vandetanib-N-oxide in human hepatic microsomes.
2.4. Oxidation of Vandetanib by Human Recombinant CYP and FMO Enzymes
The use of recombinant CYP enzymes expressed in Supersomes™ in combination with their
reductase, POR, was another approach to examine the activity of individual human CYP enzymes
to oxidize vandetanib. Under the experimental conditions used, several tested CYPs were capable
of oxidizing vandetanib to N-desmethylvandetanib, but not to vandetanib-N-oxide (Figure 5A).
Of the CYPs tested, five human CYPs were active in catalyzing the vandetanib oxidation to
N-desmethylvandetanib (Figure 5A). Of these, human CYP3A4 was the most prominent enzyme
oxidizing vandetanib with efficiencies up to one order of magnitude higher than those of the other CYPs
(i.e., CYP2D6, 1A1, 2C8 and 3A5) (Figure 5A). Cytochrome b5, the heme protein participating in several
functions of the CYP-monooxygenase system [25–37], influenced N-desmethylvandetanib formation
catalyzed by several CYPs. The strongest impact of cytochrome b5 on this reaction was seen with
human CYP3A4. The potency of human CYP3A4 to oxidize vandetanib was 8-fold higher (p < 0.001)
when additionally stimulated by cytochrome b5. Cytochrome b5 also increased the formation of
N-desmethylvandetanib in reactions catalyzed by CYP3A5 (7-fold; p < 0.001) and CYP2C8 (1.6-fold;
p < 0.01). In contrast, essentially no such effect was observed when testing human CYP1A1 and 2D6
(Figure 5A). These results indicate that not only the expression and activities of these CYPs alone,
but also the expression levels of cytochrome b5 can influence the metabolism of vandetanib in humans.
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Figure 5. Oxidation of vandetanib to N-desmethylvand t i by human recombinant CYPs (A) and
FMOs (B). Values represent mean ± SD of three independent in vitro incubations (n = 3). *** p < 0.001,
** p < 0.01 significant differences between formation of N-desmethylvandetanib by CYP enzymes with
and without cytochrome b5 (b5) in Panel (A) and *** p < 0.001 significant differences between formation
of vandetanib-N-oxide in Panel (B). (ANOVA with post-hoc Tukey HSD Test). ND—not detected.
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Similarly, the potency of human recombinant FMO1, FMO3 and FMO5 enzymes to metabolize
vandetanib was evaluated using Supersomes™. In contrast to recombinant CYPs, recombinant FMOs
were not able to oxidize vandetanib to N-desmethylvandetanib, but generated vandetanib-N-oxide
(Figure 5B). FMO1 was over 5 times more efficient to form vandetanib-N-oxide than FMO3 (Figure 5B).
The FMO3 enzyme is expressed in human liver, whereas FMO1 is not expressed in this human
organ [38,39]. Therefore, it can be speculated that the formation of vandetanib-N-oxide is catalyzed by
FMO3 in human hepatic microsomes.
2.5. Contributions of Individual CYPs to Oxidation of Vandetanib to N-Desmethylvandetanib in Human Livers
Based on the results showing the velocities of vandetanib oxidation to N-desmethylvandetanib
in experimental systems containing recombinant CYP enzymes in Supersomes™ (Figure 6) and the
relative amounts of CYP enzymes expressed in human livers [40–44], the contributions of individual
CYPs to this reaction in human livers were evaluated. For these calculations we also took the presence
and absence of cytochrome b5 into account. The highest contribution to N-desmethylvandetanib
formation in human liver was attributed to CYP3A4 (~97.7%), followed by CYP2D6 (~1.7%) and
CYP1A1, 2C8 and 3A5 (all less than ~0.3%) (Figure 6A). However, the pattern of CYP contributions
in human liver clearly changed when the effect of cytochrome b5 on vandetanib oxidation was
considered. In the presence of cytochrome b5, almost all N-desmethylvandetanib formation was
attributed to CYP3A4 (~99.6%) with almost neglectable contributions (~0.4% in total) by other human
CYPs (CYP2D6, 3A5, 1A1 and 2C8) (Figure 6B). Therefore, the impact of these CYPs on various
responses to vandetanib treatment on individual patients should be negligible.
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without consideration of the effect of cytochrome b5 (A) and with that of cytochrome b5 (B).
2.6. Binding Of Vandetanib to the Active Site of Compound I of Human CYP1A1, CYP2D6 and CYP3A4
N-Demethylation of vandetanib precedes via the CYP-mediated attack on the carbon atom of the
methyl group by oxygen of the Compound I of CYPs, which leads to the formation of theα-C-hydroxylation
product that consequently decomposes to formaldehyde and N-desmethylvandetanib (Figure 1). Therefore,
the binding affinity and orientation of the N-methyl group of vandetanib in the binary complex of vandetanib
with the CYP active site, which is a prerequisite process for vandetanib-N-demethylation, should dictate the
efficiency of individual CYPs to catalyze this reaction. Of the tested human CYP enzymes, CYP3A4, 2D6
and 1A1 were most effective in vandetanib N-demethylation (Figure 5A). Therefore, the binding affinity and
orientation of the N-methyl group of vandetanib in the binary complex of vandetanib with the active sites
of these CYPs were investigated. The flexible docking simulation found the probable productive binding
position of vandetanib molecule in the active sites of human CYP1A1 and CYP2D6 (Figure 7A,B).
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Figure 7. The binding orientations found in molecular docking calculations facilitating oxidative
demethylation of N-methyl group of vandetanib in human CYP1A1, CYP2D6 and CYP3A4 represented
by X-ray structures CYP1A1 4I8V (A), CYP2D6 3tda (B), CYP3A4 1W0E (C1); CYP3A4 6BD7 (C2);
and CYP3A4 6BD7 containing second vandetanib molecule (green) (C3). Vandetanib molecule
(pink/green) and heme (yellow) residues are rendered as bold sticks. Side-chains of amino acid residues
closely interacting with vandetanib are shown in gray. Red ribbon represents a part of helix I.
The binding positions in these CYPs (3.89 and 3.38 Å) are not optimal but facilitate N-demethylation,
and consis ently with our experiments the vand tanib is predicted to e better substrat for CYP2D6
than for CYP1A1 as it shows higher binding affinity and a more favorable reaction distance than
CYP1A1 (Table 4). The active site of CYP3A4 possesses a large and flexible binding cavity, therefore we
evaluated vandetanib interaction toward two structures of human CYP3A4, one crystallized without
ligand presence and second co-crystallized with large ritonavir-like ligand. Using molecular docking
techniques, we predicted several possible binding poses of vandetanib in the active site of human
CYP3A4, and some of them were suitable for vandetanib-N-demethylation. The obtained productive
binding poses were partially different (Figure 7C1,C2). This was not surprising because the binding sites
of both structures were slightly different and substantially larger than volume of a single vandetanib
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molecule. The binding poses found were also showing less than optimal reaction distances of 3.12 and
3.45 Å, which is not consistent with our experimental findings that CYP3A4 demethylates vandetanib
more efficiently than CYP1A1 and CYP2D6.
In order to explain the high efficiency of CYP3A4 in N-demethylation of vandetanib, we investigated
the possibility of binding the second vandetanib molecule. The second vandetanib molecule was docked
into the active site of CYP3A4 already containing one vandetanib molecule. For that we did not use the
productive complex shown in Figure 7C2, but the energetically most favorable complex found during
initial vandetanib docking, this ligand pose is rendered pink in Figure 7C3. The second ligand fitted
well into the remaining space of the binding cavity accommodating a position near the heme residue.
The productive position shows slightly lower binding energy than the first vandetanib molecule, but it
shows minimal reaction distance for N-demethylation (Table 4, Figure 7C3).
Table 4. The predicted binding free energies and distances facilitating N-demethylation of vandetanib
bound in selected CYPs.
Simulated System
The Most Stable Productive Orientations of the Neutral Form of
Vandetanib in the Complex with CYPs
Estimated Free Energy of
Binding (kcal/mol) O(Comp I)-N-CH3Distance [Å]
a
CYP1A1 (4I8V) −8.64 3.89
CYP2D6 (3TDA) −10.21 3.38
CYP3A4 (1W0E) −9.96 3.12
CYP3A4 (6BD7) −9.63 3.45
CYP3A4 (6BD7)
+ second vandetanib molecule −9.30 2.67
a Distance between the carbon in the N-methyl group of vandetanib and oxygen atom on heme iron in the complex
of an activated CYP enzymes (Compound I), see Figure 7.
Based on this theoretical approach it can be suggested that CYP3A4 in the complex with two
vandetanib molecules bound to the active center is more efficient in catalyzing the N-demethylation of
vandetanib than the classical binary complex of CYP3A4 with one vandetanib molecule. If this hypothesis
is valid and the CYP3A4 enzyme binds more than one vandetanib molecule, this should lead to sigmoidal
kinetics of vandetanib-N-demethylation. To further examine this hypothesis, we investigated the kinetics
of the CYP3A4-mediated vandetanib oxidation. As shown in Figure 8 and Table 5, CYP3A4 oxidized
vandetanib to N-desmethylvandetanib by a reaction exhibiting sigmoidal kinetics which supported our
hypothesis originating from the molecular docking results. In contrast, CYP1A1 and 2D6 N-demethylate
vandetanib by reactions exhibiting hyperbolic kinetics (Figure 8A,B), which is consistent with the models
found where one molecule of vandetanib was bound to the active sites of CYP1A1 and 2D6.
Table 5. The characteristics of the kinetics of the oxidation of vandetanib to N-desmethylvandetanib by
human CYP1A1, 2D6 and 3A4.
CYP Enzyme
Kinetical Characteristics
a VMax b K0.5 c Hill Coefficient
CYP1A1 0.76 ± 0.02 35.12 ± 2.75 NA
CYP2D6 2.16 ± 0.15 84.36 ± 18.14 NA
CYP3A4 6.17 ± 1.32 45.02 ± 13.62 1.73 ± 0.56
CYP3A4+cyt b5
34.32 ±
1.59 83.65 ± 5.55 1.83 ± 0.13
Values represent means ± SD of three independent in vitro incubations (n = 3). a VMax—maximal velocity of
N-desmethylvandetanib formation (peak area/min/nmol CYP); b K0.5—the substrate concentration corresponding
to half-maximal velocity (µM); c Hill coefficient–Hill cooperativity index. Hill cooperativity index of n = 1.73 for
CYP3A4 and 1.83 for CYP3A4 in the presence of cytochrome b5 (cyt b5) show that two substrate molecules can be
bound to the active site of the CYP3A4 enzyme. NA—not applicable.
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(A), 2D6 (B), 3A4 (C) and this enzyme in the presence of cytochrome b5 (D). Values represent means ±
SD of three independent in vitro incubations (n = 3).
The presence of cytochrome b5 in the CYP3A4 system significantly increased the rate of vandetanib
oxidation but did not influence the type of kinetics (Figure 8C,D). Similar values of Hill coefficient of
the reactio were found both for the free CYP3A4 form and CYP3A4 in complex with cytochrome b5
indicating that kinetics did not change. Cytochrome b5 strongly facilitated the velocity of the oxidative
reaction and increased also the value of K0.5, indicating that a higher vandetanib concentration
is required to attain half-maximal velocity. The K0.5 doubles with and without cytochrome b5,
which suggests that possibly the allosteric effects of this heme protein may be affecting catalysis
by altering the enzymatic affinity. The complex mechanism of the CYP3A4 kinetics for vandetanib
oxidation to N-desmethylvandetanib should be considered. The CYP3A4 activity can be affected (i) by
binding of two molecules of vandetanib to the active site, resulting in the sigmoid kinetics (positive
cooperativity), and (ii) by binding of a non-substrate ligand acting as activator (cytochrome b5) at a site
other than the substrate binding site (an allosteric modulation).
3. Discussion
The results of this study demonstrate that N-desmethylvandetanib and vandetanib-N-oxide,
the two major oxidation products of vandetanib, are formed by human, rat, rabbit and mouse hepatic
microsomes in vitro. However, the profile of vandetanib metabolites formed by microsomes isolated
from different species varied significantly, especially in the amounts of generated vandetanib-N-oxide.
Human hepatic microsomes were less efficient in the generation of vandetanib metabolites compared
to hepatic microsomes isolated from rat, rabbit and mice. These findings can result from distinctive
expression levels of CYPs and FMOs and/or from different efficiencies of orthologue forms of these
enzymes in microsomes of these species that modulate the oxidation of vandetanib. The expression
levels of the selective CYP and FMO enzymes were indeed significantly different in hepatic microsomes
of human and the tested animal models. In human liver, the CYP3A4 enzyme is predominantly
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expressed and the major CYP of this organ (~30% of the CYP liver complement). This is in contrast
to CYPs of the 2C subfamily (~15% for CYP2C9) and CYP1A2 (~13%) that are also highly expressed
in this organ but are less abundant [40], whereas in rat liver, CYPs of the 2C subfamily are mainly
expressed (~55% of the CYP rat liver complement) instead of enzymes of the CYP3A (~15%) and CYP1A
(~2%) subfamilies. Likewise, in the livers of rabbits and mice, CYP2C are the major CYPs expressed
in this organ [40–43,45,46]. Of the FMO enzymes, FMO3 (as well as FMO5) is known to be highly
expressed in human and mouse liver [38,39], whereas FMO1 is not expressed in the human liver but it
is the major FMO form expressed in the livers of rats and rabbits. Therefore, this distinct expression
of individual liver CYP and FMO enzymes support the hypothesis on their impact on differences
in vandetanib oxidation found in human and animal hepatic microsomes. Moreover, it should be
emphasized that although the metabolic pathways of vandetanib were the same in human and several
animal species [10,19], from the point of view of the CYP- and FMO-generated amounts of individual
vandetanib metabolites, rat, rabbit and mouse experimental models differed significantly. Therefore,
they are not suitable to mimic the metabolic situation in human.
In our study, we utilized several approaches to identify individual CYP and FMO enzymes
oxidizing vandetanib. First, we investigated the effect of agents capable of decreasing the activities of
individual CYPs and FMO. Ketoconazole, an inhibitor of CYP3A4, was the strongest inhibitor of the
oxidation of vandetanib to N-desmethylvandetanib, while sulfaphenazole and quinidine that inhibit
CYP2C and 2D, respectively, were less efficient. Inhibitors of other CYPs such as α-NF, diamantane and
DDTC inhibiting CYP1A, 2B and 2E1, respectively, showed no inhibitory effects. Further, all tested CYP
inhibitors were not capable of decreasing the formation of vandetanib N-oxide. Instead, the formation
of this metabolite was strongly attenuated by methimazole, an inhibitor of FMO [30,31]. However, it is
important to point out that results found with inhibitors are sometimes difficult to interpret because
inhibitors can act more efficiently with one enzyme substrate than another. This might explain why
itraconazol—which is considered a strong inhibitor of CYP3A4—exhibited a low potency to inhibit
vandetanib oxidation to N-demethylation product, as described previously [10]. We therefore employed
additional experimental approaches: (i) correlation analysis between the CYP- and FMO-catalytic
activities in each microsomal sample with the amounts of vandetanib metabolite(s) formed by the
same microsomes; and (ii) analysis of the oxidation of vandetanib to N-desmethylvandetanib and
vandetanib-N-oxide by human recombinant CYPs and FMOs. Our results demonstrated a predominant
role of CYP3A4 and FMO3 in the formation of N-desmethylvandetanib and vandetanib-N-oxide
in human liver microsomes, respectively.
The fact that CYP3A4 is not only responsible for the majority of vandetanib oxidation to
N-desmethylvandetanib but also the most abundant CYP found in human liver (when average 30% of
total CYP in the human liver is considered) underlines the importance of this CYP in metabolizing
vandetanib in human liver. However, the catalytic activity of CYP3A4 shows large interindividual
variability depending on many factors. Expression differs from 30% to 60% of total CYP in human
tissues but also genetic polymorphisms and modulation of CYP3A4 expression by other xenobiotics
including drugs and the diet can contribute to interindividual differences in the CYP3A4-mediated
pharmacokinetic profiles of vandetanib. Moreover, oxidation of vandetanib by CYP3A4 as the
most prominent enzyme forming N-desmethylvandetanib is strongly stimulated by cytochrome b5.
In addition to these phenomena, the mechanism of catalysis of vandetanib oxidation by CYP3A4
determines its high efficacy in this reaction. Molecular modeling indicated that binding of more than
one molecule of vandetanib into the CYP3A4-active center occurs, which is responsible for the sigmoid
kinetics of vandetanib oxidation and the high efficiency of CYP3A4 to N-demethylate vandetanib.
Our finding that CYP3A4 activity can be modulated by binding of two molecules of the vandetanib
substrate and by allosteric modulation by cytochrome b5 might be of great importance because the
distribution of vandetanib in the human body can lead to differences in its concentrations in various
human tissues. The sigmoidal kinetics of vandetanib binding to CYP3A4 strongly dictates its oxidation
(N-demethylation) and might thus result in different response in patients to treatment with this drug.
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All these features can lead to different anticancer activity and/or adverse effects after vandetanib
treatment. Indeed, this conclusion seems to be valid because distinct responses to vandetanib have
been found in several patients suffering from medullary thyroid cancer treated with this drug [47].
However, in order to further support this conclusion, it will be important to monitor the marker
enzyme activity of CYP3A4 in patients with the medullary thyroid cancer that have been shown to
differ in their response to vandetanib and to correlate the phenotypic activity of CYP3A4 to clinical data
that shows the patient’s responses to vandetanib treatment. In addition, future studies should consider
drug–drug interactions related to CYP3A4 that are known to modulate the pharmacokinetic profiles of
various anticancer drugs [21] and included when evaluating different patient’s responses to vandetanib
treatment. These considerations, although beyond the scope of the present study, should help to
optimize and personalize chemotherapy with vandetanib.
Even though vandetanib-N-oxide was determined to be a minor metabolite formed in human liver,
our finding that FMO1 and FMO3 can efficiently catalyze the formation of this metabolite is of high
significance. Namely, the formation of vandetanib-N-oxide significantly decrease the pharmacological
effects of vandetanib, since it is more than 50-times less pharmacological active than vandetanib or
N-desmethylvandetanib [10]. In contrast to human liver, the FMO1 enzyme that is most efficient
to catalyze oxidation of vandetanib to vandetanib-N-oxide, is highly expressed in human kidney,
lung, bone marrow, and gastrointestinal tract, where it can decrease the oxidation of vandetanib to
this less efficient vandetanib metabolite. Therefore, the expression and enzymatic activities of FMO1
in these organs and FMO3 in human liver can determine the anticancer properties of vandetanib.
Moreover, levels of FMOs and their activities have been reported to be modulated by developmental
and hormonal changes rather than by exogenous compounds in several mammals including humans,
dictating their final activities [48–50]. Since the FMO inhibitor methimazol is commonly used as
a drug to treat hyperthyroidism in humans [31,51] it could be envisaged to be used as a modulator
of FMO-mediated vandetanib oxidation thereby providing a new strategy to improve the anticancer
efficiency of treatment of thyroid cancer patients with vandetanib. This remains a challenge for
future research.
4. Materials and Methods
4.1. Chemicals and Material
Vandetanib was from LC Laboratories (Woburn, MA, USA). Ketoconazole, NADPH, methimazol and
other chemicals were all purchased from Sigma-Aldrich (St. Louis, MO, USA). The purity of all chemicals
met the standards of American Chemical Society, unless noted otherwise. All animal experiments were
conducted in accordance with the Regulations for the Care and Use of Laboratory Animals (311/1997,
Ministry of Agriculture, Czech Republic), which follows the Declaration of Helsinki. Male Wistar rats
(~125–150 g; AnLab, Czech Republic), male C57BL/6 mice (5–8 g; CXR Bioscience Ltd., Dundee, UK),
and male New Zealand rabbits (2.5–3 kg; AnLab, Czech Republic) were employed as animal models.
Animals were placed in cages in temperature- and humidity-controlled rooms, acclimatized for five days
and maintained at 22 ◦C with a 12 h light/dark period. Standardized diet and water were provided ad
libitum. Rats, mice and rabbits used to prepare microsomal fraction from untreated animals were sacrificed
by cervical dislocation, livers snap-frozen in liquid nitrogen and stored at −80 ◦C until further processing
(see below). For controls, livers of the animals were removed immediately after sacrifice, divided into
small pieces (~1 g), snap-frozen in liquid nitrogen, and stored at −80 ◦C until isolation of microsomal
fractions. Pooled microsomes were used for all in vitro experiments in the present study and prepared
from 10 livers/group for all animal species following established protocols [52,53]. Microsomal fractions
were stored at −80 ◦C until analysis. Protein concentrations in the microsomal fractions were assessed
using the bicinchoninic acid protein assay with bovine serum albumin as a standard [54]. Male human
hepatic microsomes (pooled sample) (sample LOT: 3043885) were from Gentest Corp. (Woburn, MA, USA).
Microsomes from livers of twelve human donors were obtained from Gentest Corp. (Woburn, MA, USA) (cat.
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no. HG43–1, HG103, HG74, HG93, HG24, HG27, HG23, HG32, HK31, HK34, HG03, and HG42). Each human
microsomal sample has been characterized for CYP, FMO and protein contents and specific CYP activities by
Gentest Corp. We reanalyzed each microsomal preparation for specific CYP, NADPH:CYP reductase (POR)
and FMO activities by assays described in the protocols of Gentest Corp. Our data were similar to those
reported by Gentest Corp. in their specification sheets. The content of CYP, specific CYP and FMO activities
in each human hepatic microsomes [phenacetin-O-deethylation (CYP1A2), coumarin-7-hydroxylation
(CYP2A6), (S)-mephenytoin-N-demethylase (CYP2B6), paclitaxel-6α-hydroxylation (CYP2C8), diclofenac-4’-
hydroxylation (CYP2C9), (S)-mephenytoin-4′-hydroxylation (CYP2C19), bufuralol-1’-hydroxylation
(CYP2D6), chlorzoxazone-6-hydroxylation (CYP2E1), testosterone-6β-hydroxylation (CYP3A4), lauric
acid-12-hydroxylation (CYP4A), methyl-p-tolyl sulfide oxidase (FMO)] are shown in Table 2. Human
recombinant enzymes were used in the forms of Supersomes™ and obtained from Gentest Corp.
In Supersomes™microsomal fractions were isolated from insect cells that are transfected with baculovirus
constructs containing cDNA of human CYP enzymes (CYP1A1/2, 1B1, 2A6, 2B6, 2C8/9/18/19/, 2D6, 2E1,
3A4). These Supersomes™ also express NADPH:CYP oxidoreductase (POR). However, because they are
microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic
reticulum membrane (like NADH:cytochrome b5 reductase and cytochrome b5) are also expressed at
basal levels in these Supersomes™. We also utilized Supersomes™ which over-expressed cytochrome
b5, in a molar ratio of CYP to cytochrome b5 of 1 to 5. In Supersomes™ where cytochrome b5 was not
over-expressed (see above) pure cytochrome b5 was added to reach a molar ratio of CYP to cytochrome
b5 of 1 to 5. Reconstitution of Supersomes™ with purified cytochrome b5 was performed as described
previously [35,55–57]. Human recombinant FMOs were also used in the forms of Supersomes™ (Gentest
Corp.). These microsomal fractions were isolated from insect cells that are transfected with baculovirus
constructs containing cDNA of human FMO1, FMO3 and FMO5 enzymes.
4.2. Oxidation of Vandetanib by Hepatic Microsomes and CYP Enzymes
Unless stated otherwise, incubation mixtures used to study vandetanib metabolism contained
the following in a final volume of 500 µl for incubations containing hepatic microsomes and 250 µL
for incubations with Supersomes™: 100 mM potassium phosphate buffer (pH 7.4), 1 mM NADPH,
human, rat, rabbit or mouse hepatic microsomes (0.25 mg protein) (500 µl), or human recombinant
CYPs or FMOs in SupersomesTM (100 pmol) (250 µL) and 50 µM vandetanib dissolved in 5 µL dimethyl
sulfoxide (DMSO). The reaction was initiated by adding vandetanib. In control incubations, either
microsomes or CYP (FMO) or NADPH or vandetanib were omitted. Incubations were performed at
37 ◦C for 20 min in open plastic Eppendorf tubes; vandetanib oxidation was linear up to 30 min of
incubation. After the incubations, 5 µL of 1 mM phenacetine (dissolved in methanol) was added as
internal standard. The reaction was stopped by extraction with dichlormethane (2 × 1 mL). Extracts
were evaporated, dissolved in 25 µl methanol and high-performance liquid chromatography (HPLC)
analysis was used to separate vandetanib and its metabolites. HPLC conditions were as follows:
Nucleosil®EC 100-5 C18 reverse phase column (150 × 4.6 mm, Macherey Nagel); the eluent was 0,5%
v/v triethylamin in water (pH 3) containing 30% acetonitrile with a flow rate of 0.6 ml/min, detection
was at 254 nm. Vandetanib metabolites separated HPLC were characterized by mass spectrometry
(see further details below). Up to two vandetanib metabolites were detected with the retention
times (r.t.) of 7.6 and 8.9 min, corresponding to N-desmethylvandetanib and vandetanib-N-oxide,
respectively. The recoveries of vandetanib metabolites were approximately 95%.
4.3. Identification of Vandetanib Metabolites by Mass Spectrometry
Vandetanib metabolites were identified by direct infusion of diluted sample in 50% acetonitrile
in water plus 1% acetic acid into the 12T solariX XR FT-ICR mass spectrometer (Bruker Daltonics,
Bremen, Germany). The mass spectrometer was operating in positive ion mode. Calibration of the
instrument was performed using 1% solution of sodium trifluoracetic resulting in accuracy below
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2 ppm. Data acquisition and data processing were performed by ftmsControl 2.1.0 and DataAnalysis
4.2 (Bruker Daltonics).
4.4. Inhibition Studies
Inhibition studies in human liver microsomes were essentially conducted as reported previously [58].
The inhibitors employed were as follows: α-Naphthoflavone (α-NF), which inhibits CYP1A1 and 1A2;
diamantane, which inhibits CYP2B; sulfaphenazole, which inhibits CYP2C; quinidine, which inhibits CYP2D;
diethyldithiocarbamate (DDTC), which inhibits CYP2E1 and CYP2A; and ketoconazole, which inhibits
CYP3A. The values of IC50 using 0.05–500 µM concentrations of inhibitors were also determined by the
procedure described previously [59]. Inhibitors were dissolved in 5 µL DMSO, except for quinidine and
α-naphthoflavone which were dissolved in methanol and except of DDTC, which was dissolved in water,
yielding a final concentration of 50 µM in the incubation mixtures [equimolar concentrations of individual
inhibitors with those of vandetanib (50 µM) were in incubation mixtures]. Inhibitors were incubated at 37 ◦C
for 10 min with the 50 µM vandetanib prior to addition of NADPH, and then mixtures were incubated for
further 20 min at 37 ◦C. The formation of vandetanib metabolites was analyzed by HPLC as described above.
4.5. Contributions of CYP Enzymes to N-Demethylation of Vandetanib to N-Desmethylvandetanibin
in Human Livers
In order to calculate the contributions of individual CYPs to vandetanib oxidation (i.e. formation
of N-desmethylvandetanib) in human livers, we utilized the velocities of vandetanib oxidation to
N-desmethylvandetanib by the Supersomal CYP enzyme systems in combination with reported data
on the expression levels of CYPs in human livers [40–43]. The contributions of these enzymes were
calculated by relative activity factor because the activities of CYPs in Supersomes™ also need to be
considered in addition to the relative contents of CYPs in the livers. Therefore, the contribution of
each CYP enzyme that oxidizes vandetanib in livers was calculated by dividing the relative activity
of each CYP oxidizing vandetanib [r.a.cypi] (rate of vandetanib oxidation to N-desmethylvandetanib)
multiplied by the amounts of this CYP in tissues examined, by the total relative activities (
∑
[r.a.cypi])
of all CYPs oxidizing this substrate. Of CYPs in human liver, CYP3A4 is the major enzyme present
in this human organ (~30% of the CYP hepatic complement), followed by CYP2C9 and 1A2 (~15% and
~13%, respectively), while CYP2C19, 2E1 2A6, 2D6, 2C8 and 3A5 are present in human liver at levels
that range from ~2.5% to ~8.5% (see Reference [40] for an overview).
4.6. Molecular Docking of Vandetanib into Compounds I of Human CYP1A1, 2D6 and 3A4
The X-ray based coordinates of human CYP1A1 (PDB ID 4I8V) [60], CYP2D6 (PDB ID 3TDA) [61],
CYP3A4 ligand-free form (2.8 Å resolution, PDB ID 1W0E) [62] and inhibitor (ritonavir-like ligand)
bound form (2.42 Å resolution, PDB ID 6BD7) [63] were used as starting structures for modeling
of vandetanib interactions with the activated state—Compound I of selected human CYPs. During
structure preparation, hydrogen atoms were added and crystallographic water and ligand molecules
were removed, usual protonation states and Gasteiger partial charges were assigned to all residues,
except for the atomic charge of the ferric ion of the heme cofactor, for which a value more consistent
with a metal in octahedral coordination was used [64]. The geometries and charges of a vandetanib
ligand in neutral form were predicted using ab initio calculations on the Hartree–Fock level of theory
in conjunction with the 6–31+G(d) basis set. All ab initio calculations were carried out with program
Gaussian 09 [65]. Autodock v4.2.6 was employed for flexible docking using procedure described
previously [66]. All rotatable bonds of the residues S122, F123, F224, F258, D313, N222, L496, D320,
T321 (in CYP1A1) or F120, F483, L213, E216 (in 2D6) and vandetanib ligand were allowed to rotate
freely. We carried out an extensive search (1000 docking runs per system) of the most preferred binding
modes of vandetanib molecule within a 60×60×60 Å grid-box centered on the substrate binding cavity.
Resulting structures showing RMSD lower than 2.0 Å were grouped and finally sorted by binding
free energy of the best binding structure within each cluster. A set of binding modes with similar
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binding energies was found for every system as a result. We assume that only the orientations with
a sufficiently short distance between carbon of the N-methoxy group of vandetanib and the activated
oxygen atom in the CYP Compound I would facilitate the N-demethylation reaction.
4.7. Statistical Analysis
Data are expressed as mean ± SD. Data was analyzed using GraphPad Prism 7 using ANOVA
with post-hoc Tukey HSD Test. p-value < 0.05 was considered as significant. Statistical associations
between CYP- and FMO-linked catalytic activities in human hepatic microsomal samples and amounts
of N-desmethylvandetanib and vandetanib-N-oxide formed by the same microsomes were determined
by linear regression using Statistical Analysis System software version 6.12. Correlation coefficients
(r) were based on a sample size of twelve for human microsomes. All p values are two-tailed and
considered significant at the 0.01 level.
5. Conclusions
N-desmethylvandetanib and vandetanib-N-oxide were identified as the two major oxidation products
of vandetanib, the drug used for the treatment of symptomatic or progressive medullary thyroid cancer due
to the RET tyrosine kinase mutation occurring in this type of thyroid cancer. They are generated by human,
rat, rabbit and mouse hepatic microsomes in vitro. In the human hepatic microsomal systems, CYP3A4
>>>> CYP2D6 >> CYP1A1 are important in the formation of N-desmethylvandetanib, while FMO3
oxidizes vandetanib to vandetanib-N-oxide. The oxidation of vandetanib by CYP3A4, the most prominent
enzyme catalyzing formation of N-desmethylvandetanib, is stimulated by cytochrome b5. We further
elucidated the molecular mechanism of vandetanib-N-demethylation catalyzed by CYP3A4, which might
be of great importance to optimize the treatment regimen of the drug. Molecular modeling (in silico
docking) and sigmoid kinetics of the reaction demonstrated that two molecules of vandetanib are bound
to the CYP3A4-active center. This process results in a shift of orientation of the N-methyl group of
vandetanib to be located closer to oxygen of the CYP3A4 Compound I leading to an optimal reaction
distance for N-demethylation. The novel results showing the allosterically modulated CYP3A4-catalyzed
oxidation of vandetanib, in addition to a new finding of a decrease in FMO-mediated generation of
vandetanib-N-oxide by methimazol, are challenges for further investigation and potential utilization to
improve treatment of thyroid cancer with vandetanib.
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EGFR epidermal growth factor receptor
FMO flavin-containing monooxygenase
HPLC high-performance liquid chromatography
POR NADPH:CYP oxidoreductase
RET rearranged during transfection
r.t. retention time
TIE2 tyrosine kinase with immunoglobulin and EGF domains-2
TK tyrosine kinase
TKI tyrosine kinase inhibitor
VEGFR-2 vascular endothelial growth factor receptor
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